uniQure to Host Research & Development Day on Monday, November 19 in New York City

~ Event to be Webcast Live on Corporate Website ~

LEXINGTON, Mass and AMSTERDAM, the Netherlands, Nov. 05, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will host a Research & Development Day on Monday, November 19, 2018 in New York City, from 8:30 a.m. – 12:00 p.m. EST.

The event will include presentations on new research programs that expand the Company’s gene therapy pipeline, feature advancements in research technology and provide updates on current programs. In addition, the Research and Development Day will include presentations from Christopher A. Ross, M.D., Ph.D., Professor of Psychiatry, Neurology and Neuroscience at the Johns Hopkins School of Medicine, and Annette Von Drygalski, M.D., PharmD, Director of the Hemophilia and Thrombosis Treatment Center at the University of California San Diego.

The full program will be webcast live under the investor relations section of uniQure’s website at . Please connect to the webcast several minutes prior to the start of the event to ensure the connection. A conference call will also be provided for those who opt to listen to the event by telephone. The listen-only conference call can be accessed by dialing 646-828-8193 (domestic) or 1 (international). The passcode for the call is 5853244. Please specify to the operator that you would like to join the “uniQure R&D Day 2018”. A replay of the webcast will be available at uniQure’s website for 45 days following the event.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases.

uniQure Contacts: